ArticleBMC microbiology2026
Prevalence and molecular characterization of colistin-resistant gram-negative bacteria from a tertiary care hospital in Eastern India.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColistin, a last resort antibiotic for multidrug resistant gram-negative infections, is facing enhanced resistance. Data from Eastern India, including Odisha, is limited, highlighting the importance for enhanced surveillance to monitor emerging resistance and guide appropriate empirical therapy.
objectiveThis study aimed to screen for colistin resistance and to evaluate the antimicrobial susceptibility patterns among gram-negative bacteria isolated from clinical samples.
methodThe study period was from February 2024 to January 2025, during which 366 non-duplicate identified clinical samples were collected from SUM hospital, Bhubaneswar. Antimicrobial susceptibility testing, including colistin tested at three concentrations (10, 25, and 50 µg), was performed using the Kirby-Bauer disk diffusion method. As CLSI and EUCAST guidelines do not recommend disk diffusion for colistin due to poor agar diffusion, the results were considered screening-only and were not used to determine confirmed susceptibility or resistance, and mcr-1 to mcr-9 genes were screened by PCR; however, mcr-1, mcr-3, and mcr-4 were not detected in any of the isolates. Descriptive statistics, including percentages and 95% confidence intervals, were used to summarize prevalence and screening-based colistin non-susceptibility findings.
resultMost frequently isolated organisms were E. coli (36.88%) and K. pneumoniae (19.67%). Screen-positive colistin non-susceptibility was observed highest in K. pneumoniae (59.72%), P. aeruginosa (29.62%) and E. coli (8.14%). Multiple mcr genes were detected among screen-positive isolates, with K. pneumoniae positive for mcr-2, 5, 6, 7, 8, 9, E. coli was positive for mcr-5 and mcr-8, A. baumannii for mcr-2, 6, 7 and mcr-1, mcr-3, and mcr-4 were absent in all isolates; P. aeruginosa harboured mcr-7 & mcr-9 only. K. pneumoniae, E. coli and A. baumannii showed high multidrug resistance patterns. These findings are based on screening-positive results only. Prevalence estimates of screening-based colistin non-susceptibility were interpreted descriptively, and 95% confidence intervals were calculated for bacterial isolates and clinical sample sources where appropriate.
conclusionThis study highlights screen-positive colistin non-susceptibility among gram-negative isolates in Odisha, India. These screening-based observations underscore the need for confirmatory testing using broth microdilution and ongoing molecular surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.